Combined therapy with sulbactam/ampicillin and aztreonam for bacterial infections associated with hematological disease.

DOI 7 References
  • Nakao Mitsushige
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Ueda Kyoji
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Akano Yumiko
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Nomura Kenichi
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Fujita Yasuko
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Okamoto Tomomi
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Kobayashi Miyako
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Iwai Toshiki
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Sasai Yuri
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Nakazawa Naozo
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Yokota Shohei
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Horiike Shigeo
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Taniwaki Masafumi
    Third Department of Internal Medicine, Kyoto Prefectual University of Medicine
  • Nisigaki Hikaru
    Department of Internal Medicine, Ohtsu Municipal Hospital
  • Kaneko Hiroto
    Department of Internal Medicine, Aiseikai Yamashina Hospital

Bibliographic Information

Other Title
  • 血液疾患に併発した重症感染症に対するｓｕｌｂａｃｔａｍ／ａｍｐｉｃｉｌｌｉｎとａｚｔｒｅｏｎａｍの併用療法

Search this article

Description

Combined antibacterial therapy with sulbactam/ampicillin (SBT/ABPC) and aztreonam (AZT) was given to 51 patients with infections associated with hematological disease. Among the 41 evaluable patients, 15 (36.6%) had acute leukemia, 18 (43.9%) malignant lymphoma, 6 (14.6%) multiple myeloma, 1 (2.4 %) myelodysplatic syndrome, and 1 (2.4%) chronic lymphocytic leukemia. The overall response to this treatment was 61.0%, and those for individual infections were 65.5% for suspected sepsis and 60.0% for pneumonia. The response was 66.7% for patients with acute leukemia, and 58.8% those with malignant lymphoma. In elderly patients, response is relatively low. Patients with neutropenia are resistant to current antibacterial therapy. No side effects of a high grade were seen in evaluable patients. This combination therapy is effective for various infections in patients with hematological malignancy.

Journal

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top